P-21 at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
P-21 (also referred to as P21) is a small tetrapeptide developed by researchers studying the active fractions of Cerebrolysin. It was designed to replicate and amplify the neurogenic properties of Cerebrolysin's low-molecular-weight peptide fraction by specifically targeting BDNF signaling and hippocampal neurogenesis.
P-21 acts by binding to a site on the NCAM (Neural Cell Adhesion Molecule) receptor that amplifies BDNF/TrkB signaling without directly binding to TrkB itself. This mechanism promotes neurogenesis, synaptic plasticity, and neuroprotection. Animal studies have shown that P-21 significantly increases hippocampal cell proliferation, improves spatial memory in aged rodents, and protects against neuroinflammation.
P-21 is not approved for clinical use and human data is absent - it remains a research compound. However, it has attracted interest among neurohackers for its targeted BDNF-enhancing mechanism and its connection to the well-established Cerebrolysin research base.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.